Dr. Garfall Discusses CAR T-Cell Therapy in Multiple Myeloma


Alfred L. Garfall, MD, MS, discusses the potential of CAR T-cell therapy in multiple myeloma.

Alfred L. Garfall, MD, MS, assistant professor of medicine, the Hospital of the University of Pennsylvania, discusses the potential of CAR T-cell therapy in multiple myeloma.

CAR T-cell therapy has shown high response rates in heavily pretreated and high-risk patients multiple myeloma, says Garfall.

The modality has been shown to lead to extended treatment-free remissions. Although the majority of patients with multiple myeloma who receive CAR T-cell therapy will relapse, the modality has shown potential for long-term immune surveillance against relapse, concludes Garfall.

Related Videos
Paul Harmatz, MD
Mark Walters, MD
Mitchel Horwitz, MD
Bruce Cree, MD, PhD, MAS, a professor of neurology and the clinical research director of the University of California San Francisco (UCSF) Multiple Sclerosis Center
Emilie Aschenbrenner, PharmD, BCOP, a hematology coordinator for pharmacy at Froedtert and the Medical College of Wisconsin
Raj Chovatiya, MD, PhD
Jessica S. Little, MD, a transplant infectious diseases physician at Dana-Farber Cancer Institute
Nirav N. Shah, MD
Alexis Kuhn, PharmD, BCOP, a pediatric oncology pharmacist at the Mayo Clinic
Haydar Frangoul, MD
© 2024 MJH Life Sciences

All rights reserved.